摘要In 2014, the World Health Organization was notified of an outbreak of a communicable disease characterized by fever, severe diarrhea, vomiting, and a high fatality rate in Guinea. Virologic investigation identified Zaire ebolavirus (EBOV) as the causative agent. Approximately 30 years after the first epidemic, there is no vaccine or therapeutic medication approved to counter the Ebola virus. In this review, it emphasized that plant based antibodies can be an effective cure to Ebola hemorrhagic fever. Genetically modified Nicotiana benthamiana is used to manufacture ZMapp drug by Kentucky BioProcessing. ZMapp three-antibody cocktail binds to the Ebola virus to deactivate it and provides simulated immune response against sugar-tagged proteins on the outside of the Ebola virus, which had verified efficacy against Ebola infection in nonhuman primates and also successfully treated two American medical workers infected with Ebola virus disease.